RLMD - Relmada jumps after long-term Phase 3 data for anti-depressant
2023-09-20 09:30:02 ET
More on Relmada
- Seeking Alpha’s Quant Rating on Relmada Therapeutics
- Historical earnings data for Relmada Therapeutics
- Financial information for Relmada Therapeutics
- Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout
- Relmada Therapeutics, Inc. (RLMD) Q2 2023 Earnings Call Transcript
For further details see:
Relmada jumps after long-term Phase 3 data for anti-depressant